Ariad Pharmaceuticals logo Ariad Pharmaceuticals (NASDAQ:ARIA) announced its earnings results on Wednesday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05, StockRatingsNetwork.com reports. The company had revenue of $11.80 million for the quarter, compared to the consensus estimate of $10.41 million. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.26 moved to $7.28 on last trade day and at the end of the day closed at $6.75. Company price to sales ratio in past twelve months was calculated as 27.65 and price to cash ratio as 5.32. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -7.15%.
Gilead Sciences Inc. (NASDAQ:GILD), the maker of a hepatitis C treatment projected to be the best-selling drug of all time, said it would double the size of an existing $5 billion share buyback program. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.57% in last trading session and ended the day on $78.77. GILD return on equity ratio is recorded as 38.90% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 48.26%.
VIVUS, Inc. (NASDAQ:VVUS) For the three months ended March 31, 2014, net loss was $15.6 million or $0.15 net loss per share, as compared to a net loss of $53.6 million or $0.53 net loss per share during the same period in 2013. VIVUS, Inc. (NASDAQ:VVUS) shares moved down -1.17% in last trading session and was closed at $5.50, while trading in range of $5.32 – $5.57. VIVUS, Inc. (NASDAQ:VVUS) year to date (YTD) performance is -39.43%.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced that on May 1, 2014, Aegerion granted stock options to purchase an aggregate of 27,750 shares of common stock to 16 new employees under the inducement stock option program. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) weekly performance is -21.76%. On last trading day company shares ended up $34.63. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) distance from 50-day simple moving average (SMA50) is -27.64%. Analysts mean target price for the company is $97.20.
Leave a Reply